Abstract:Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00763?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00763</a>.Virtual screening results from the molecular docking; compounds identified as hits against RORγ from virtual screening; overlaid complex structures of compound XY101 and compound 27h; overlaid structures of compounds 27g and 27h; western blot analysis of the AR and AR variants levels in 22Rv1 cells treated with compound 27h; metabolic stability of 25c, 25p, 27g, and 27h in human and rat liver microsomes; 1H and 13C NMR spectra of the synthesized compounds; and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_001.pdf">PDF</a>)Molecular formula strings for compounds with associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_002.csv">CSV</a>)Database files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of Biaryl Amides As Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors.

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

Discovery of tert-amine-based RORγt agonists.

Discovery of Carbazole Carboxamides As Novel RORγt Inverse Agonists.

Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.

Discovery of <i>tert</i>-amine-based RORt agonists

Discovery of N-indanyl Benzamides As Potent RORγt Inverse Agonists

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

From RORγt Agonist to Two Types of RORγt Inverse Agonists.

Discovery of novel and potent sulfonamide derivatives as orally available drug for psoriasis

Discovery of Tetrahydroquinolines and Benzomorpholines As Novel Potent Ror Gamma T Agonists

Discovery of potent iminoheterocycle BACE1 inhibitors

Discovery of 3,5-Diaryl-1h-pyrazol-based Ureas As Potent RET Inhibitors.

Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[ d ]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD)

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist